James Joseph Martin

CIK: 0001510224

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

COCP

Cocrystal Pharma, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

COCP
Cocrystal Pharma, Inc.
Jan 9, 2026
Award(A)
Stock Options (Right to Buy)
Direct
49.2K shares-
COCP
Cocrystal Pharma, Inc.
Oct 28, 2025
Award(A)
Direct
3.6K shares at avg. $1.39$5K
COCP
Cocrystal Pharma, Inc.
Oct 9, 2024
Award(A)
Direct
40K shares-

		Type	Shares	Price		Ownership
Jan 9, 2026	COCP Cocrystal Pharma, Inc.	Award(A) Stock Options (Right to Buy)	49,229	-	-	Direct
Oct 28, 2025	COCP Cocrystal Pharma, Inc.	Award(A)	3,598	$1.39	$5,001	Direct
Oct 9, 2024	COCP Cocrystal Pharma, Inc.	Award(A)	40,000	-	$0	Direct

1-3 of 3 transactions

About Martin James Joseph

Martin James Joseph (SEC CIK 0001510224) files insider reports with the SEC as Co-CEO and CFO of Cocrystal Pharma, Inc. (COCP).

Signal8 holds 3 ownership filings by Martin James Joseph, all Form 4s, filed between Oct 11, 2024 and Jan 13, 2026. Those filings report 3 transactions, from Oct 9, 2024 to Jan 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Martin James Joseph's filings is in MIAMI, FL.

Recent filings by Martin James Joseph

Jan 9, 2026: Grant or award of COCP derivative securities (Form 4, code A).
Oct 28, 2025: Grant or award of COCP shares (Form 4, code A).
Oct 9, 2024: Grant or award of COCP shares (Form 4, code A).

Other insiders filing for Cocrystal Pharma, Inc. (COCP)

Brosgart Carol L, Director
FROST PHILLIP MD ET AL, Director
SAPIRSTEIN JAMES, Chief Executive Officer
Kornberg Roger D., Director
PFENNIGER RICHARD C JR, Director
Lee Sam, President and Co-CEO

How to read Form 4 transaction codes